Taking cellular immunotherapy to the next level

We are focused on the development of stem cell-derived Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer. NK cells are the new star in the domain of cellular immunotherapy, due to their tightly regulated “natural killing” of cancer cells; they play an important role in control and even cure of both solid and hematological malignancies, like acute myeloid leukemia (AML) and multiple myeloma (MM).


Our lead investigational product

oNKord® is an off-the-shelf, Natural Killer (NK) cellular immunotherapy product. Based on umbilical cord blood (UCB) derived CD34+ stem cells, oNKord® has many advantages, such as off-the-shelf, readily available with minimum waiting time; safe, since oNKord® does not cause Cytokine Release Syndrome (CRS) and cost-effective.

Glycostem Pipeline

Glycostem is developing our pipeline of cellular immunotherapy therapies, which has the potential to redefine standards of care across various type of cancer. Besides of oNKord® as our lead investigational product, we are developing viveNKTM, Chimeric Antigen Receptor (CAR)-engineered NK cell therapy and also T-cell receptor expression NK cell products. Our vision is to be the leading innovative NK cell therapy company covering strong unmet medical needs.

oNKord® phase I/IIa pivotal trial


Glycostem initiated phase I/IIa pivotal trial to evaluate the safety and efficacy of oNKord® in patients with Acute Myeloid Leukemia (AML) in November 2020. The WiNK trial will enrol 33 AML patients in total, in 5 European countries. The recruitment of patients for the WiNK trial is open.


Pioneering, developing and manufacturing

Over the last decade we studied the role of NK cells in cancer treatment extensively and pioneered, developed and optimized our in-house NK-cell production processes.During our phase I safety study we verified our lead product oNKord® (naked NK cells) to be a safe therapeutic agent in the field of cellular immunotherapy. Currently we are developing our second generation product: Chimseric Antigen Receptor (CAR)-engineered NK cells. A growing number of commercial and academic partners have chosen Glycostem because of our expertise with NK cells and their production.

Press releases

Glycostem donates funding to the Acute Leukemia Advocates Network and Leukaemia Care

11th May 2021 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, announced the donation to the Acute Leukemia Advocates Network (ALAN) and to Leukaemia Care. 

Glycostem enters into Material Transfer Agreement with Pieris to enhance solid tumor targeting capabilities of Glycostem’s oNKord® and CAR-NK treatments

12th March, 2021 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf

Glycostem and Ghent University sign license agreement on NK cell therapy technology

17th December, 2020 - Glycostem Therapeutics and Ghent University (UGent) have signed a license agreement for an inn